Research Unit UMR6014 Rouen Normandie University, CNRS, INSA |
Organic and Bioorganic Chemistry, Reactivity, Analysis |
COBRA |
HeadPr Xavier Pannecoucke |
ContactCNRS UMR 6014 IRCOF Rue Tesnière 76130 Mont Saint-Aignan Phone: +33 235 52 2920 cobra@insa-rouen.fr pannecoucke@insa-rouen.fr |
Research Topics
|
Composition
|
Facilities
|
ActivityThe COBRA unit is structured around six general scientific themes (analysis and modelling, bioorganic chemistry, synthesis of fluorinated molecules, organometallics, heterocycles & supramolecular and supported chemistry) and mainly works in the areas of organic, bioorganic, medicinal and analytic chemistryAmong applications, the preparation of compounds with biological interest, in collaboration with biology and pharmacy teams, takes a significant place. The goal of the bioorganic component is the preparation of biologically active compounds for various domains (cancer, cardiovascular, SNC, antiviral), the vectorization of active substances and the synthesis of probes and bioconjugates used in molecular imaging. The analysis and modelling component provides a support for the chemists to solve structural problems and develops its own research projects at the chemistry-biology interface. These projects are the structural characterization of peptide and protein domains by NMR and molecular modelling as well as the characterization of neuropeptide and GPCR interactions by NMR. The fact that the COBRA teams benefit from national and international recognition is shown by the numerous invitations, collaborations, and financed projects (ANR, Oséo, FEDER, Interreg, PAI-PHC). The unit has developed strong working relationships with academics and industrial leaders in pharmacy and biotechnology by the Technopôle Chimie-Biologie Santé, the “center for competiveness” Cosmetic valley, and the federal group, PharmaValley. Most of the teams of the unit have developed during this period, strong and durable partnerships with the industry of the pharmaceutical sector (SERVIER, ORIL, SANOFI-AVENTIS, JANSSEN/CILAG, VALDEPHARM, NUFARM, ISOCHEM, EXONIT Therapeutics, ROQUETTE Bros., AAA) and from foundational chemistry (TOTAL, ARKEMA). ). A compound is in clinical development (a Servier Laboratoires collaboration) and IRIS Biotech has commercialized three compounds originating from research in bioorganic chemistry from the group. The group also brings important support for the creation of start ups in biotechnology by welcoming the parties involved on its premises. QUIDD (medical imagery) and POLYINTELL (Innovative polymers for diagnostics) have been hosted for several years in the group. Two start-ups have been created due to the group’s work: TFChem in 2007 (fluorinated sugar for the pharmaceutical industry) and CNS vector in 2011 (vectorization of active principals and radiotracers on the central nervous system). |
Main Contributions
|
Main Publications2013
2012
|